Entos Entered into an Agreement with BioMarin for Gene Therapies to Treat Genetic Diseases
Shots:
- Entos will use its Fusogenix nucleic acid delivery system to develop BioMarin products for multiple genetic diseases. BioMarin will be responsible for the preclinical studies of the Fusogenix-formulated products for the prevention of diseases
- The agreement will use Entos' Fusogenix proteolipid vehicle nucleic acid delivery platform with BioMarin's pipeline to develop gene therapies. Entos' Fusogenix platform provides benefits for safe and effective tissue compared with other lipid-based delivery systems
- Entos' Covigenix VAX-001 and two genetic adjuvants are designed to stimulate host adaptive and innate immune systems
Ref: PR Newswire | Image: BioMarin
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
